LitAlert ~~ GeneLit.com

    • MicroRNA-449a Inhibits Triple Negative Breast Cancer by Disturbing DNA Repair and Chromatid Separation.
    • Vajen B, Bhowmick R, Greiwe L, Schäffer V, Eilers M, Reinkens T, Stalke A, Schmidt G, Fiedler J, Thum T, DeLuca DS, Hickson ID, Schlegelberger B, Illig T, Skawran B.
    • Int J Mol Sci. 2022 May 4;23(9):5131. doi: 10.3390/ijms23095131.
    • Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052).
    • Asano H, Oda K, Yoshihara K, Ito YM, Matsumura N, Shimada M, Watari H, Enomoto T.
    • J Gynecol Oncol. 2022 May 3. doi: 10.3802/jgo.2022.33.e55. Epub ahead of print.

    Trial ID: jRCT2031210264: Phase 2 Study to Evaluate the Efficacy and Safety of Niraparib in Recurrent or Persistent Rare Gynecologic Malignancies with Homologous Recombination Deficiency (JGOG2052). (Japanese Registry of Clinical Trials)

    • Estrogen and BRCA1 deficiency synergistically induce breast cancer mutation-related DNA damage.
    • Chen J, Liu J, Zeng P, Zhao C, Liu X, Sun J, Wang J, Fang P, Chen W, Ding J.
    • Biochem Biophys Res Commun. 2022 May 2;613:140-145. doi: 10.1016/j.bbrc.2022.04.142. Epub ahead of print.